Pentamidine reverses the splicing defects associated with myotonic dystrophy

Area of Science:

• Molecular Biology
• Genetics
• RNA Biology

Background:

• Myotonic dystrophy (DM) is a genetic disorder characterized by expanded RNA repeats.
• The alternative splicing factor MBNL1 is sequestered by these repeats, leading to mRNA missplicing and DM symptoms.
• Releasing MBNL1 from sequestration is a potential therapeutic strategy for DM.

Purpose of the Study:

• To identify small molecules that disrupt MBNL1 binding to expanded RNA repeats.
• To evaluate the therapeutic potential of identified compounds in DM models.

Main Methods:

• In vitro assays to test compound disruption of MBNL1-RNA binding.
• Cell culture experiments to assess reversal of pre-mRNA missplicing and ribonuclear foci formation.
• In vivo studies in mouse models of DM.

Main Results:

• Pentamidine and neomycin B were identified as compounds disrupting MBNL1 binding to CUG repeats in vitro.
• Pentamidine reversed missplicing of two pre-mRNAs in cell culture and reduced ribonuclear foci.
• Pentamidine partially rescued splicing defects in a mouse model of DM, while neomycin B had no effect.

Conclusions:

• Pentamidine demonstrates therapeutic potential for myotonic dystrophy by alleviating key molecular defects.
• Targeting MBNL1 sequestration by expanded repeats is a viable strategy for DM treatment.
• Pentamidine represents a promising lead compound for further development as a DM therapy.